A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.
Introduction: Current prescribing guidelines for the antipsychotic amisulpride are based largely on pharmacokinetic (PK) studies in young adults, and there is a relative absence of data on older patients, who are at greatest risk of developing adverse events. Methods: This study aimed to develop a p...
| Publicado en: | Psychopharmacology Vol. 233; no. 18; pp. 3371 - 3382 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Sep2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=117509702&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 117509702 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00333158 EJD jtl: Psychopharmacology issn: 00333158 maglogo: N pubinfo: dt: Sep2016 vid: 233 iid: 18 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 117509702 10.1007/s00213-016-4379-6 117509702 ppf: 3371 ppct: 11 formats: fmt: @attributes: type: P tig: atl: A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease. aug: au: Reeves, Suzanne Bertrand, Julie D'Antonio, Fabrizia McLachlan, Emma Nair, Akshay Brownings, Stuart Greaves, Suki Smith, Alan Taylor, David Howard, Robert affil: UMR 1137 IAME INSERM University Paris 7, France and Genetics Institute, University College London , London UK sug: ab: Introduction: Current prescribing guidelines for the antipsychotic amisulpride are based largely on pharmacokinetic (PK) studies in young adults, and there is a relative absence of data on older patients, who are at greatest risk of developing adverse events. Methods: This study aimed to develop a population PK model for amisulpride specifically in older people, by combining data from a richly sampled phase 1, single (50 mg) dose study in healthy older people ( n = 20, 65-79 years), with a clinical dataset obtained during off label, low-dose (25-75 mg daily) amisulpride prescribing in older people with Alzheimer's disease (AD) ( n = 25, 69-92 years), as part of an observational study. Results: After introducing a scaling factor based on body weight, age accounted for 20 % of the inter-individual variability in drug clearance (CL), resulting in a 54 % difference in CL between those aged 65 and those aged 85 years, and higher blood concentrations in older patients. Discussion: These findings argue for the consideration of age and weight-based dose stratification to optimise amisulpride prescribing in older people, particularly in those aged 85 years and above. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|